The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma

Deming Duan, Keke Wang, Cheng Wei, Dudu Feng, Yonghua Liu, Qingyan He, Xing Xu, Chunling Wang, Shuping Zhao, Leili Lv, Jing Long, Danni Lin, Ai Zhao, Bingmu Fang, Jinhong Jiang, Shixing Tang, Jimin Gao, Deming Duan, Keke Wang, Cheng Wei, Dudu Feng, Yonghua Liu, Qingyan He, Xing Xu, Chunling Wang, Shuping Zhao, Leili Lv, Jing Long, Danni Lin, Ai Zhao, Bingmu Fang, Jinhong Jiang, Shixing Tang, Jimin Gao

Abstract

Chimeric antigen receptor (CAR) technology has revolutionized cancer treatment, particularly in malignant hematological tumors. Currently, the BCMA-targeted second-generation CAR-T cells have showed impressive efficacy in the treatment of refractory/relapsed multiple myeloma (R/R MM), but up to 50% relapse remains to be addressed urgently. Here we constructed the BCMA-targeted fourth-generation CAR-T cells expressing IL-7 and CCL19 (i.e., BCMA-7 × 19 CAR-T cells), and demonstrated that BCMA-7 × 19 CAR-T cells exhibited superior expansion, differentiation, migration and cytotoxicity. Furthermore, we have been carrying out the first-in-human clinical trial for therapy of R/R MM by use of BCMA-7 × 19 CAR-T cells (ClinicalTrials.gov Identifier: NCT03778346), which preliminarily showed promising safety and efficacy in first two enrolled patients. The two patients achieved a CR and VGPR with Grade 1 cytokine release syndrome only 1 month after one dose of CAR-T cell infusion, and the responses lasted more than 12-month. Taken together, BCMA-7 × 19 CAR-T cells were safe and effective against refractory/relapsed multiple myeloma and thus warranted further clinical study.

Keywords: BCMA; CAR-T; CCL19; IL-7; multiple myeloma.

Conflict of interest statement

AZ and JG were employed by Zhejiang Qixin Biotech. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Duan, Wang, Wei, Feng, Liu, He, Xu, Wang, Zhao, Lv, Long, Lin, Zhao, Fang, Jiang, Tang and Gao.

Figures

Figure 1
Figure 1
Efficient expression of CAR on lentiviral-transduced T cells and functional verification of IL-7 and CCL19. (A) Schematic representation of BCMA-hBBz CAR and BCMA-7x19 CAR. (B) CAR expressions of CAR-T cells were analyzed by flow cytometry. The numbers in scatter plots represent the percentages of positively stained cells. (C) The expression rates of BCMA CAR and BCMA-7x19 CAR. Data are means± SD obtained from seven donors. MOI = 80. P-value was calculated by two-tailed student t-test. ns, not statistically significant (P > 0.05). (D) Quantitative detection of IL-7 (left) and CCL19 (right) secretion by ELISA. (E) Number fold change of BCMA-hBBz and 7 × 19 CAR-T cells at the indicated time-points. ****P < 0.0001 by two-way ANOVA. (F) The count of migrating T cells (N = 3). ****P < 0.0001 was calculated by two-tailed student t-test. ***P < 0.001.
Figure 2
Figure 2
Phenotype of CAR-T cell. (A) Expression of CD45RA and CD45RO on CAR-T cells subsets in CD62L+ cells by flow cytometry. Tcm (CD62L+CD45RO+CD45RA−), Tscm (CD62L+CD45RO−CD45RA+). (B) Statistical chart of subset distribution. (C) CD4/CD8 ratios of CAR-T cells were analyzed by flow cytometry. (D) Change of Tscm ratio at the indicated time-points. P-value was calculated by two-way ANOVA. *P < 0.05, ****P < 0.0001.
Figure 3
Figure 3
Cytotoxicity analysis of BCMA-hBBz and 7 × 19 CAR-T cells in vitro and in vivo. (A) MM1S-Luc-GFP, U266-Luc-GFP and BCMA-K562 cell lines stably expressing BCMA and luciferase. (B) CAR-T cells and target tumor cells were co-incubated for 4 h at the indicated E:T ratios. Cytotoxicity assay with BCMA-K562 (left), MM1S-Luc-GFP (middle) and U266-Luc-GFP cells as targets (right). Differences between groups were determined using two-way ANOVA. Mean ± SD, ****p < 0.0001. (C) Cytokine release by CAR-T cells in response to multiple myeloma cell lines. CAR-T or mock-T cells were incubated with MM1S-Luc-GFP cells at 1:1 for 24 h, IL2 (left), IFN-γ (middle) and GM-CSF (right) were analyzed by intracellular staining or ELISA. P-value was calculated by two-tailed student t-test. ***P < 0.001. ns, not statistically significant (P > 0.05). (D) Flow chart of animal experimentation. (E). On day 0, NSG mice were injected intravenously with 4 × 106 BCMA-K562 cells. On day 7, mice received 6 × 106 BCMA-7 × 19 CAR-T cells (n = 3), BCMA-hBBz CAR-T cells (n = 3) or mock-T cells (n = 3). Luciferase bioluminescent imaging analysis on days 7, 10, 17, and 24. (F) Average bioluminescent signal for each group in different days [mean radiance (p/s/cm2/sr)] ±SD.
Figure 4
Figure 4
Clinical efficacy after BCMA-7 × 19 CAR-T infusion. (A) Duration of response and survival after BCMA-7X19 CAR-T cell infusion. (B) Scheme for CAR-T preparation and treatment. (C) Patient 1, serum immunoglobulin IgG, IgA, IgM are in the normal range, both before and after infusion. (D) Patient 1, representative CT scans at different baselines (baseline1: First extramedullary recurrence of multiple myeloma; 1 year after Len and DXM induction therapy shown in baseline 2: progression of extramedullary recurrence; baseline 3: 1 month before BCMA-7X19 CAR-T infusion); and CT scans post-CAR-T cell infusion 1, 4, and 10 months. Scale bars, 1 cm. (E) Patient 2, monitoring of urine light chain protein and (F) Serum immunoglobulin IgG, Ig A, Ig M levels before and after treatment. (G) Serum kinetics of a panel of cytokines in patients who received infusions with high doses of CAR-T cells, as determined by Luminex multiplex assay (R&D Systems) Horizontal lines denote mean values.

References

    1. Chmielewski M, Abken H. TRUCKs: the fourth-generation of CARs. Exp Opin Biol Ther. (2015) 15:1145–54. 10.1517/14712598.2015.1046430
    1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. (2011) 364:1046–60. 10.1056/NEJMra1011442
    1. Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, et al. . Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. (2018) 131:301–10. 10.1182/blood-2017-07-795047
    1. Duong CP, Yong CS, Kershaw MH, Slaney CY, Darcy PK. Cancer immunotherapy utilizing gene-modified T cells: from the bench to the clinic. Mol Immunol. (2015) 67:46–57. 10.1016/j.molimm.2014.12.009
    1. Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. (2015) 36:494–502. 10.1016/j.it.2015.06.004
    1. Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. . Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. (2018) 378:449–59. 10.1056/NEJMoa1709919
    1. Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. . Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. (2016) 8:355ra116. 10.1126/scitranslmed.aaf8621
    1. Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, et al. . Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. (2020) 13:30. 10.1186/s13045-020-00856-8
    1. Jia H, Wang Z, Wang Y, Liu Y, Dai H, Tong C, et al. . Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation. J Hematol Oncol. (2019) 12:57. 10.1186/s13045-019-0741-6
    1. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. (2013) 3:388–98. 10.1158/-12-0548
    1. Ewen C, Kane KP, Shostak I, Griebel PJ, Bertram EM, Watts TH, et al. . A novel cytotoxicity assay to evaluate antigen-specific CTL responses using a colorimetric substrate for Granzyme B. J Immunol Methods. (2003) 276:89–101. 10.1016/S0022-1759(03)00073-5
    1. Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. (2014) 257:83–90. 10.1111/imr.12125
    1. Tian Y, Li Y, Shao Y, Zhang Y. Gene modification strategies for next-generation CAR T cells against solid cancers. J Hematol Oncol. (2020) 13:54. 10.1186/s13045-020-00890-6
    1. Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood. (2017) 130:2594–602. 10.1182/blood-2017-06-793869
    1. Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, et al. . T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. (2018) 36:2267–80. 10.1200/JCO.2018.77.8084
    1. Bu DX, Singh R, Choi EE, Ruella M, Nunez-Cruz S, Mansfield KG, et al. . Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget. (2018) 9:25764–80. 10.18632/oncotarget.25359
    1. Berahovich R, Zhou H, Xu S, Wei Y, Guan J, Guan J, et al. . CAR-T cells based on novel BCMA monoclonal antibody block multiple myeloma cell growth. Cancers. (2018) 10:323. 10.3390/cancers10090323
    1. Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, et al. . A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. (2017) 31:2278. 10.1038/leu.2017.219
    1. Xu J, Wang Q, Xu H, Gu C, Jiang L, Wang J, et al. . Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. J Hematol Oncol. (2018) 11:128. 10.1186/s13045-018-0672-7
    1. Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. . T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. (2016) 128:1688–700. 10.1182/blood-2016-04-711903
    1. Brown FD, Turley SJ. Fibroblastic reticular cells: organization and regulation of the T lymphocyte life cycle. J Immunol. (2015) 194:1389–94. 10.4049/jimmunol.1402520
    1. Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. (2018) 36:346–51. 10.1038/nbt.4086
    1. Jiang Q, Li WQ, Aiello FB, Mazzucchelli R, Asefa B, Khaled AR, et al. . Cell biology of IL-7, a key lymphotrophin. Cytok Growth Factor Rev. (2005) 16:513–33. 10.1016/j.cytogfr.2005.05.004
    1. Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol. (2001) 22:564–71. 10.1016/S1471-4906(01)02028-2
    1. Geiselhart LA, Humphries CA, Gregorio TA, Mou S, Subleski J, Komschlies KL. IL-7 administration alters the CD4:CD8 ratio, increases T cell numbers, and increases T cell function in the absence of activation. J Immunol. (2001) 166:3019–27. 10.4049/jimmunol.166.5.3019
    1. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA. (1998) 95:258–63. 10.1073/pnas.95.1.258
    1. Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Aït-Yahia S, et al. . Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med. (1998) 188:373–86. 10.1084/jem.188.2.373
    1. Yoshida R, Nagira M, Imai T, Baba M, Takagi S, Tabira Y, et al. . EBI1-ligand chemokine (ELC) attracts a broad spectrum of lymphocytes: activated T cells strongly up-regulate CCR7 and efficiently migrate toward ELC. Int Immunol. (1998) 10:901–10. 10.1093/intimm/10.7.901
    1. Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. . International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. (2016) 34:1544–57. 10.1200/JCO.2015.65.0044
    1. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. (2014) 124:188–95. 10.1182/blood-2014-05-552729
    1. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. . International uniform response criteria for multiple myeloma. Leukemia. (2006) 20:1467–73. 10.1038/sj.leu.2404284
    1. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. . Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. (2011) 117:4691–5. 10.1182/blood-2010-10-299487
    1. Bradley LM, Haynes L, Swain SL. IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol. (2005) 26:172–6. 10.1016/j.it.2005.01.004
    1. Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer. (2012) 12:671–84. 10.1038/nrc3322
    1. Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, et al. . Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. (2020) 38:775–83. 10.1200/JCO.19.02657
    1. Blaeschke F, Stenger D, Kaeuferle T, Willier S, Lotfi R, Kaiser AD, et al. . Induction of a central memory and stem cell memory phenotype in functionally active CD4 and CD8 CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19 acute lymphoblastic leukemia. Cancer Immunol Immunother. (2018) 67:1053–66. 10.1007/s00262-018-2155-7
    1. Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, et al. . Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. (2017) 35:1803–13. 10.1200/JCO.2016.71.3024
    1. Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. . Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. (2016) 34:1112–21. 10.1200/JCO.2015.64.5929
    1. Friedman KM, Garrett TE, Evans JW, Horton HM, Latimer HJ, Seidel SL, et al. . Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Human Gene Ther. (2018) 29:585–601. 10.1089/hum.2018.001
    1. Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. (2019) 34:45–55. 10.1016/j.blre.2018.11.002
    1. Raje NS, Berdeja JG, Lin Y, Munshi NC, Siegel DS, Liedtke M, et al. . bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study. J Clin Oncol. (2018) 36:8007–7. 10.1200/JCO.2018.36.15_suppl.8007
    1. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. . Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. (2019) 380:1726–37. 10.1056/NEJMoa1817226
    1. Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, et al. . Recent advances in CAR-T cell engineering. J Hematol Oncol. (2020) 13:86. 10.1186/s13045-020-00910-5
    1. van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev. (2015) 14:499–509. 10.1038/nrd4597
    1. Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, et al. . Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. (2015) 28:415–28. 10.1016/j.ccell.2015.09.004
    1. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. . Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. (2015) 33:540–9. 10.1200/JCO.2014.56.2025
    1. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. (2014) 371:1507–17. 10.1056/NEJMoa1407222
    1. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. . T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. (2015) 385:517–28. 10.1016/S0140-6736(14)61403-3
    1. Pellegrini M, Calzascia T, Toe JG, Preston SP, Lin AE, Elford AR, et al. . IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell. (2011) 144:601–13. 10.1016/j.cell.2011.01.011
    1. Pellegrini M, Calzascia T, Elford AR, Shahinian A, Lin AE, Dissanayake D, et al. . Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med. (2009) 15:528–36. 10.1038/nm.1953
    1. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, et al. . Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Investig. (2005) 115:1616–26. 10.1172/JCI24480
    1. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Investig. (2007) 117:1466–76. 10.1172/JCI32446
    1. Paulos CM, Suhoski MM, Plesa G, Jiang T, Basu S, Golovina TN, et al. . Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res. (2008) 42:182–96. 10.1007/s12026-008-8070-9
    1. Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, Jr, et al. . Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. (2016) 44:380–90. 10.1016/j.immuni.2016.01.021
    1. Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. . Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. (2018) 24:563–71. 10.1038/s41591-018-0010-1
    1. Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, et al. . IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. (2013) 121:573–84. 10.1182/blood-2012-05-431718
    1. Elsawa SF, Novak AJ, Grote DM, Ziesmer SC, Witzig TE, Kyle RA, et al. . B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood. (2006) 107:2882–8. 10.1182/blood-2005-09-3552
    1. Deshayes F, Laprée G, Portier A, Richard Y, Pencalet P, Mahieu-Caputo D, et al. . Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor. Oncogene. (2004) 23:3005–12. 10.1038/sj.onc.1207350

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere